These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21763213)

  • 21. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rectal morbidity following I-125 prostate brachytherapy in relation to dosimetry.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M
    Jpn J Clin Oncol; 2007 Feb; 37(2):121-6. PubMed ID: 17255159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.
    Pai HH; Keyes M; Morris WJ; Christie J
    Brachytherapy; 2013; 12(2):126-33. PubMed ID: 22738665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
    Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
    Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
    Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.
    Valdagni R; Rancati T; Fiorino C; Fellin G; Magli A; Baccolini M; Bianchi C; Cagna E; Greco C; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Vavassori V
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1065-73. PubMed ID: 18234449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
    Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.
    Price JG; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):842-7. PubMed ID: 23845840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
    van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.
    Wallner K; Roy J; Harrison L
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):465-71. PubMed ID: 7751187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.
    Cesaretti JA; Stock RG; Atencio DP; Peters SA; Peters CA; Burri RJ; Stone NN; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1410-6. PubMed ID: 17490827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.
    Sherertz T; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W; True L
    Brachytherapy; 2004; 3(3):130-5. PubMed ID: 15533804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Permanent prostate brachytherapy in prostate glands <20 cm(3).
    Mayadev J; Merrick GS; Reed JR; Butler WM; Galbreath RW; Allen ZA; Wallner KE
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1450-5. PubMed ID: 20338476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.